Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 3/20 | 0.63 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.59 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.57 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | TFPI | P10646 | 1/20 | 0.57 |
| ▸ | GLP1R | P43220 | 4/20 | 0.56 |
| ▸ | GIPR | P48546 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31332122 | 0.98 | CALCR (0.64) | CALCRCRHR1CRHR2OPRD1OPRM1 | |
| SCHEMBL29516785 | 0.98 | CALCR (0.64) | CALCRCRHR1CRHR2OPRD1OPRM1 | |
| SCHEMBL11650961 | 0.97 | OPRD1 (0.60) | CALCROPRD1OPRM1OPRK1KEAP1 | |
| SCHEMBL11667794 | 0.96 | CALCR (0.64) | CALCRCRHR1CRHR2OPRD1OPRM1 | |
| SCHEMBL30439066 | 0.96 | CALCR (0.66) | CALCRCRHR1CRHR2OPRD1OPRM1 | |
| SCHEMBL11650974 | 0.95 | OPRD1 (0.62) | CALCROPRD1OPRM1OPRK1 | |
| SCHEMBL11664809 | 0.95 | CALCR (0.63) | CALCRCRHR1CRHR2OPRD1OPRM1 | |
| SCHEMBL11667808 | 0.95 | CALCR (0.63) | CALCRCRHR1CRHR2OPRD1OPRM1 | |
| SCHEMBL11652679 | 0.95 | CALCR (0.65) | CALCRCRHR1CRHR2OPRD1OPRM1 | |
| SCHEMBL11651841 | 0.95 | CALCR (0.65) | CALCRCRHR1CRHR2OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | claimed |
| US-12624063-B2 | Compositions and methods for modification of target molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260015381-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF TARGET MOLECULES | UNIV CALIFORNIA (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250243257-A1 | BINDING-TRIGGERED TRANSCRIPTIONAL SWITCHES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-07-31 | — | — | US | disclosed |
| US-20250122309-A1 | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same | OMEROS CORP (US) | 2025-04-17 | — | — | US | disclosed |
| EP-4486301-A1 | GASTRORETENTIVE FORMULATIONS CONTAINING PROTEIN OR PEPTIDE | APeT Holding B.V. (NL) | 2025-01-08 | — | — | EP | disclosed |
| US-20240400639-A1 | ENGINEERED EXTRACELLULAR RECEPTOR CONSTRUCTS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
| US-12060591-B2 | Tau protease compositions and methods of use | OLIGOMERIX, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| CN-111164211-B | Compositions and methods for treating beta-hemoglobinopathies | 杰特贝林基因治疗股份有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-117886949-A | Transcription switch combined with triggering and using method thereof | 加利福尼亚大学董事会 | 2024-04-16 | — | — | CN | disclosed |
| US-20240043845-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES | CSL BEHRING GENE THERAPY INC (US) | 2024-02-08 | — | — | US | disclosed |
| CN-108064283-B | Binding triggered transcription switches and methods of use thereof | 加利福尼亚大学董事会 | 2024-01-09 | — | — | CN | disclosed |
| US-11795461-B2 | Compositions and methods for treating beta-hemoglobinopathies | CSL BEHRING GENE THERAPY, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-2968546-B1 | METHODS OF GENERATING BIOACTIVE PEPTIDE-BEARING ANTIBODIES AND COMPOSITIONS COMPRISING THE SAME | OMEROS CORP (US) | 2023-09-20 | — | — | EP | disclosed |
| WO-2023166224-A1 | GASTRORETENTIVE FORMULATIONS CONTAINING PROTEIN OR PEPTIDE | APET Holding B.V. (NL) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023022845-A2 | GRAM-NEGATIVE BACTERIA CONTAINING PEPTIDE SECRETION SYSTEM | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-02-23 | — | — | WO | disclosed |
| EP-3698832-B1 | METHODS AND DEVICES FOR SMOKING URGE RELIEF | FONTEM HOLDINGS 1 BV (NL) | 2022-07-13 | — | — | EP | disclosed |
| US-20220153779-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF TARGET MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-05-19 | — | — | US | disclosed |
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624063-B2 | Compositions and methods for modification of target molecules | TYR, TH, COMT | CALCR 1781/4885CRHR1 4076/4885CRHR2 3849/4885 |
| US-20260015381-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF TARGET MOLECULES | TH, COMT, TYR | CALCR 3279/4885CRHR1 4871/4885CRHR2 4860/4885 |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | CALCR 118/4885CRHR1 195/4885CRHR2 386/4885 |
| US-20220153779-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF TARGET MOLECULES | COMT, TH, AOX1 | CALCR 3731/4885CRHR1 4241/4885CRHR2 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.